tradingkey.logo
tradingkey.logo

Lifecore Biomedical Inc

LFCR
View Detailed Chart
3.736USD
-0.134-3.46%
Market hours ETQuotes delayed by 15 min
98.65MMarket Cap
LossP/E TTM

Lifecore Biomedical Inc

3.736
-0.134-3.46%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.46%

5 Days

-7.06%

1 Month

-48.11%

6 Months

-47.75%

Year to Date

-54.33%

1 Year

-45.46%

View Detailed Chart

Key Insights

Lifecore Biomedical Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lifecore Biomedical Inc's Score

Industry at a Glance

Industry Ranking
67 / 157
Overall Ranking
174 / 4542
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Lifecore Biomedical Inc Highlights

StrengthsRisks
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Growing
The company is in a growing phase, with the latest annual income totaling USD 75.52M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -6.80, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.24M shares, decreasing 5.79% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.60K shares of this stock.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
6.500
Target Price
+67.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lifecore Biomedical Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Lifecore Biomedical Inc Info

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Ticker SymbolLFCR
CompanyLifecore Biomedical Inc
CEOJosephs (Paul)
Websitehttps://www.lifecore.com/
KeyAI